283 related articles for article (PubMed ID: 18350604)
1. Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma.
Matsuda Y
World J Gastroenterol; 2008 Mar; 14(11):1734-40. PubMed ID: 18350604
[TBL] [Abstract][Full Text] [Related]
2. p16 and p27 are functionally correlated during the progress of hepatocarcinogenesis.
Matsuda Y; Ichida T
Med Mol Morphol; 2006 Dec; 39(4):169-75. PubMed ID: 17187177
[TBL] [Abstract][Full Text] [Related]
3. Loss of p16 contributes to p27 sequestration by cyclin D(1)-cyclin-dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma.
Matsuda Y; Ichida T; Genda T; Yamagiwa S; Aoyagi Y; Asakura H
Clin Cancer Res; 2003 Aug; 9(9):3389-96. PubMed ID: 12960127
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of cell cycle inhibitors in hepatocellular carcinoma.
Matsuda Y; Wakai T; Kubota M; Takamura M; Yamagiwa S; Aoyagi Y; Osawa M; Fujimaki S; Sanpei A; Genda T; Ichida T
Med Mol Morphol; 2013 Dec; 46(4):185-92. PubMed ID: 23640750
[TBL] [Abstract][Full Text] [Related]
5. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.
Ito Y; Matsuura N; Sakon M; Miyoshi E; Noda K; Takeda T; Umeshita K; Nagano H; Nakamori S; Dono K; Tsujimoto M; Nakahara M; Nakao K; Taniguchi N; Monden M
Hepatology; 1999 Jul; 30(1):90-9. PubMed ID: 10385644
[TBL] [Abstract][Full Text] [Related]
6. Association of low p16INK4a and p15INK4b mRNAs expression with their CpG islands methylation with human hepatocellular carcinogenesis.
Qin Y; Liu JY; Li B; Sun ZL; Sun ZF
World J Gastroenterol; 2004 May; 10(9):1276-80. PubMed ID: 15112341
[TBL] [Abstract][Full Text] [Related]
7. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes.
McConnell BB; Gregory FJ; Stott FJ; Hara E; Peters G
Mol Cell Biol; 1999 Mar; 19(3):1981-9. PubMed ID: 10022885
[TBL] [Abstract][Full Text] [Related]
8. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
[TBL] [Abstract][Full Text] [Related]
9. Upregulator of cell proliferation predicts poor prognosis in hepatocellular carcinoma and contributes to hepatocarcinogenesis by downregulating FOXO3a.
Xie C; Song LB; Wu JH; Li J; Yun JP; Lai JM; Xie DY; Lin BL; Yuan YF; Li M; Gao ZL
PLoS One; 2012; 7(7):e40607. PubMed ID: 22815774
[TBL] [Abstract][Full Text] [Related]
10. Psoriatic epidermis is associated with upregulation of CDK2 and inhibition of CDK4 activity.
Henri P; Prevel C; Pellerano M; Lacotte J; Stoebner PE; Morris MC; Meunier L
Br J Dermatol; 2020 Mar; 182(3):678-689. PubMed ID: 31145809
[TBL] [Abstract][Full Text] [Related]
11. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
[TBL] [Abstract][Full Text] [Related]
12. Cyclin Y binds and activates CDK4 to promote the G1/S phase transition in hepatocellular carcinoma cells via Rb signaling.
Chen L; Wang X; Cheng H; Zhang W; Liu Y; Zeng W; Yu L; Huang C; Liu G
Biochem Biophys Res Commun; 2020 Dec; 533(4):1162-1169. PubMed ID: 33039146
[TBL] [Abstract][Full Text] [Related]
13. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma.
Roncalli M; Bianchi P; Bruni B; Laghi L; Destro A; Di Gioia S; Gennari L; Tommasini M; Malesci A; Coggi G
Hepatology; 2002 Aug; 36(2):427-32. PubMed ID: 12143052
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the cell cycle regulation of cdk3-associated kinase activity and the role of cdk3 in proliferation and transformation.
Braun K; Hölzl G; Soucek T; Geisen C; Möröy T; Hengstschläger M
Oncogene; 1998 Oct; 17(17):2259-69. PubMed ID: 9811456
[TBL] [Abstract][Full Text] [Related]
15. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.
Edamoto Y; Hara A; Biernat W; Terracciano L; Cathomas G; Riehle HM; Matsuda M; Fujii H; Scoazec JY; Ohgaki H
Int J Cancer; 2003 Sep; 106(3):334-41. PubMed ID: 12845670
[TBL] [Abstract][Full Text] [Related]
16. Infrequent mutations and no methylation of CDKN2A (P16/MTS1) and CDKN2B (p15/MTS2) in hepatocellular carcinoma in Taiwan.
Lin YW; Chen CH; Huang GT; Lee PH; Wang JT; Chen DS; Lu FJ; Sheu JC
Eur J Cancer; 1998 Oct; 34(11):1789-95. PubMed ID: 9893670
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte growth factor induces redistribution of p21(CIP1) and p27(KIP1) through ERK-dependent p16(INK4a) up-regulation, leading to cell cycle arrest at G1 in HepG2 hepatoma cells.
Han J; Tsukada Y; Hara E; Kitamura N; Tanaka T
J Biol Chem; 2005 Sep; 280(36):31548-56. PubMed ID: 16014626
[TBL] [Abstract][Full Text] [Related]
18. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
19. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
Reynisdóttir I; Polyak K; Iavarone A; Massagué J
Genes Dev; 1995 Aug; 9(15):1831-45. PubMed ID: 7649471
[TBL] [Abstract][Full Text] [Related]
20. Expression and hypermethylation of p27 kip1 in hepatocarcinogenesis.
Lei PP; Zhang ZJ; Shen LJ; Li JY; Zou Q; Zhang HX
World J Gastroenterol; 2005 Aug; 11(29):4587-91. PubMed ID: 16052694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
